Loading...
Market
Will Prime Medicine receive an additional development milestone payment from Bristol Myers Squibb by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Prime Medicine or Bristol Myers Squibb
Story
Prime Medicine and Bristol Myers Squibb Partner on $3.5B T-Cell Therapy Deal with $110M Upfront
Sep 30, 2024, 11:17 AM
Prime Medicine has entered into a strategic research collaboration and license agreement with Bristol Myers Squibb to develop and commercialize multiple Prime Edited Ex Vivo T-Cell therapies. As part of the agreement, Prime Medicine will receive $110 million upfront, consisting of $55 million in cash and $55 million in equity. The deal also includes potential milestone payments exceeding $3.5 billion, with $1.4 billion allocated for development milestones and $2.1 billion for commercialization milestones and royalties. This partnership aims to leverage Prime Medicine's gene editing expertise and Bristol Myers Squibb's capabilities in cell therapy.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increases by more than 50% • 25%
Increases by 25% to 50% • 25%
Changes by less than 25% • 25%
Decreases • 25%
Increases by more than 20% • 25%
Increases by 10% to 20% • 25%
Changes by less than 10% • 25%
Decreases • 25%
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
Yes • 50%
No • 50%
